Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRSAD-PVP-I
2022-500642-25-00Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of povidone-iodine in Staphylococcus aureus infection and staphylococcal carrier state, sponsored by CHU de Nantes. Primary endpoint: MRSA nasal decolonization at 6 hours. Started Jan 2023; status: completed.
02
Drugs
povidone-iodine
03
Conditions
Staphylococcus aureus infectionstaphylococcal carrier state
Beyond the preview
Go deeper on 2022-500642-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500642-25-00.